Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up

A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

Mark Vickery headshot

Top Stock Reports for Verizon, Abbott & Illinois Tool Works

Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Abbott (ABT) and Illinois Tool Works (ITW).

Urmimala Biswas headshot

Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates

Henry Schein's (HSIC) strong share gains in the North American market raise optimism.

Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top

Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.

QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss

QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.

Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid

Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.

Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates

Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

Fresenius Medical (FMS) gains from solid international revenues in Q1.

HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates

Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.

AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates

Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

Is (ABT) Outperforming Other Medical Stocks This Year?

Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates

DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q1

Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.

Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall

Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.

PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss

PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.

Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line

ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.

Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline

Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.

Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered

Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.

NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong

NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.

DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance

DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.